Advances in the Delivery, Activation and Therapeutics Applications of Bioorthogonal Prodrugs
Medicinal Research Reviews · 2025-05 · 45 (3) · 887-908
DOI: 10.1002/med.22095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 18.12.2024. Verfasst von Zhou Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Laboratory of Medicinal Chemical Biology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Prodrugs, Drug Delivery Systems. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 127 Literaturangaben. Gefördert von: This study was supported by grants from National Natural Science Foundation of China (No. 22377088 and 22207081), the National Science & Technology Major Proje….
Abstract (Originalsprache)
Traditional prodrug strategies have been leveraged to overcome many inherent drawbacks of active native drugs in the drug research and development. However, endogenous stimuli such as specific microenvironment or enzymes are relied on to achieve the prodrug activation, resulting in unintended drug release and systemic toxicity. Alternatively, bioorthogonal cleavage reaction‐enabled bioorthogonal prodrugs activation via exogenous triggers has emerged as a valuable approach, featuring spatiotemporally controlled drug release. Such bioorthogonal prodrug strategies would ensure targeted drug delivery and/or in situ generation, further circumventing systemic toxicity or premature elimination of active drugs. In recent years, metal‐free bioorthogonal cleavage reactions with fast kinetics have boomed in the bioorthogonal prodrug design. Meanwhile, transition‐metal‐catalyzed and photocatalytic deprotection reactions have also been developed to trigger prodrug activation in biological systems. Besides traditional small molecule prodrugs, gasotransmitters have been successfully delivered to specific organelles or cells via bioorthogonal reactions, and nanosystems have been devised into bioorthogonal triggers as well. Herein, we present an overview of the latest advances in these bioorthogonally‐uncaged prodrugs, focused on the delivery, activation and therapeutics applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Laboratory of Medicinal Chemical Biology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
- Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, China.
ORCID-Profile: Ya-Qiu Long
Förderung
- This study was supported by grants from National Natural Science Foundation of China (No. 22377088 and 22207081), the National Science & Technology Major Proje…
Zitieren
APA
Zhou, Z., Sun, Y., Pang, J., & Long, Y. Q. (2025). Advances in the Delivery, Activation and Therapeutics Applications of Bioorthogonal Prodrugs. Medicinal Research Reviews, 45(3), 887-908. https://doi.org/10.1002/med.22095
Vancouver
Zhou Z, Sun Y, Pang J, Long YQ. Advances in the Delivery, Activation and Therapeutics Applications of Bioorthogonal Prodrugs. Medicinal Research Reviews. 2025;45(3):887-908. doi:10.1002/med.22095
BibTeX
@article{Zhou2025,
author = {Zhou, Zhou and Sun, Yuanjun and Pang, Jing and Long, Ya-Qiu},
title = {Advances in the Delivery, Activation and Therapeutics Applications of Bioorthogonal Prodrugs},
journal = {Medicinal Research Reviews},
year = {2025},
volume = {45},
number = {3},
pages = {887--908},
doi = {10.1002/med.22095}
}
EUVIMED